Other noninvasive approaches could include targeted radionuclide scans, such as the DOTA-TATE scan for neuroendocrine tumors or prostate-specific membrane antigen (PSMA) scan for prostate cancer; however, a molecularly targeted scan for CRC does not yet exist. This evidence concerns the gene FOLH1 and prostate carcinoma.